Phaseline

Targets › RRM1

RRM1 (Ribonucleoside-diphosphate reductase large subunit): drug programs, companies and trials

16 programs from 15 companies in 63 trials: 37 Phase 2, 19 Phase 1, 5 Phase 3, 2 Phase 4; Oncology, Hematology, Immunology; next expected readout Dec 2026.

Part of the ribonucleotide reductase (RNR) complex composed of a catalytic large alpha subunit (RRM1/RR1) and a small beta subunit, either RRM2/RR2 or RRM2B/RR2B required for DNA synthesis. The active form is an alpha2beta2 heterotetramer in which the RR1-containing subunits (alpha2) catalyze reduction of ribonucleotides to deoxyribonucleotides, while the RRM2-containing subunits (beta2) provide the diferric-tyrosyl…. (UniProt, P23921)

Open in Phaseline: the race on RRM1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Jiangsu Healthy Life Innovation Medical TechnologyGemcitabine hydrochloride
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 3Locally Advanced Pancreatic Cancer; Clear Cell Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Ovarian Brenner Tumor …Dec 2026
First Affiliated Hospital, Sun Yat-Sen UniversityInduction Chemotherapy (TPF regimen)
Docetaxel, cisplatin, and 5-fluorouracil combination
Tubulin, TP53, TYMS, RRM1Phase 3Locally Advanced Nasopharyngeal CarcinomaAug 2027
InnoPharmaxD07001-Softgel Capsules
Gemcitabine, a nucleoside analog
RRM1, RRM2Phase 3Biliary Tract Cancer (BTC); Biliary Tract CancerDec 2028
Memorial Sloan Kettering Cancer CenterClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 2AMLDec 2026
Dana-Farber Cancer InstituteClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 2Langerhans Cell HistiocytosisDec 2026
Peking Union Medical College HospitalGC
Combination of gemcitabine and cisplatin
RRM1, RRM2, DCK, ERCC1Phase 2Biliary Tract Neoplasms ImmunotherapyJan 2027
M.D. Anderson Cancer CenterClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 2Recurrent Acute Lymphoblastic LeukemiaAug 2027
City of Hope Medical Centerclofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 2Adult Acute Lymphoblastic Leukemia in RemissionAug 2027
TheraviaHydroxyurea
Ribonucleoside-diphosphate reductase RR1 inhibitor
RRM1, RRM2B, RRM2Phase 2Sickle Cell Disease; Sickle Cell Anemia (HbSS); Sickle Cell Anemia in Children; Primary Immunodeficiency (PID) …Feb 2028
West China Second University HospitalClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 2Langerhans Cell Histiocytosis (LCH)Jun 2028
Nantes University HospitalClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 2Acute Myeloid Leukemia in RemissionSep 2028
Princess Maxima Center for Pediatric OncologyClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 1Relapsed Pediatric AMLDec 2026
City of Hope Medical CenterCOH29
Ribonucleotide reductase (RNR) inhibitor
RRM1, RRM2Phase 1Unspecified Adult Solid Tumor, Protocol SpecificMay 2027
Jiangsu Hansoh PharmaceuticalHS-10566
Intravesical gemcitabine delivery system
RRM1, RRM2, DCKPhase 1High-risk Non-muscle-invasive Bladder CancerApr 2028
Ekaterina LaukhtinaClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 1Advanced Urothelial CarcinomaNov 2028
Beijing Immunochina Medical Science & TechnologyFludarabine Phosphate (IM19)
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 1NHL; B-cell Acute Lymphoblastic Leukemia; Myelodysplastic Syndromes; Refractory Idiopathic Aplastic Anemia …Jun 2035

Conditions

Sickle Cell Disease (7) Sickle Cell Anemia in Children (2) Metabolic Disorders (2) Acute Myeloid Leukemia in Remission (2) Acute Myeloid Leukaemia (AML) (2) Cancer (2) Metastatic Pancreatic Adenocarcinoma (2) Recurrent Acute Lymphoblastic Leukemia (1) Langerhans Cell Histiocytosis (1) Sickle Cell Anemia (HbSS) (1) Primary Immunodeficiency (PID) (1) Sickle Cell Disease (SCD) (1)

Modalities

small molecule (10), mixed (2), protein or peptide (2), other (1)

Companies

City of Hope Medical Center (2) M.D. Anderson Cancer Center (1) Dana-Farber Cancer Institute (1) Theravia (1) First Affiliated Hospital, Sun Yat-Sen University (1) Nantes University Hospital (1) Beijing Immunochina Medical Science & Technology (1) Memorial Sloan Kettering Cancer Center (1) Jiangsu Healthy Life Innovation Medical Technology (1) Ekaterina Laukhtina (1) West China Second University Hospital (1) InnoPharmax (1) Jiangsu Hansoh Pharmaceutical (1) Princess Maxima Center for Pediatric Oncology (1) Peking Union Medical College Hospital (1)

Related targets

RRM2 (15) RRM2B (11) POLA1 (10) POLD4 (10) DCK (2) Tubulin (1) TP53 (1) TYMS (1) ERCC1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.